Eli Lilly and Company

Eli Lilly sits near the top of its 52-week range, a spot the numbers back up. Revenue grew 47% last year, earnings more than doubled. Net margin hit 35%, which is rare even in pharma. The market pays 53 times earnings for that setup, not cheap by any measure, but the Alpha Score’s momentum sub-score sits at 97 — the price trend is doing its part. The value and sentiment scores are middling, 54 and 50 respectively. That suggests the stock is fully priced for what’s already in the pipeline, not pricing in a surprise. Quality at 87 keeps the foundation solid. Next week the focus stays on GLP-1 category updates and any competitive data from Novo Nordisk. If the margin story holds, the multiple has room to stay where it is.

Eli Lilly closed near the top of its 52-week range, with shares trading above $1,100 after a multi-month rally fueled by blockbuster obesity drug sales and expanding margins. The stock carries a trailing P/E of 53, but that premium is backed by 47% revenue growth and 128% earnings expansion over the past year. Net margins hit 35%, among the widest in pharma. The Alpha Score of 74 is driven by momentum (96) and quality (87), while value and sentiment remain neutral. That split is common for growth names that have already repriced higher. The next clear catalyst is second-quarter earnings due next month. Investors will watch for updated guidance on tirzepatide supply and any read-through from competitor trial data. For now, the story holds as long as growth and margins stay on the current trajectory.

Lilly sits just below its $1208.12 52-week peak, powered by 47.4% revenue growth and a 128.8% EPS surge. The net margin of 35% reflects the pricing power of its obesity and diabetes portfolio. Momentum scores 94.8, the highest sub-score in the Alpha model, while value at 54.4 suggests the P/E of 53 is already pricing in the pipeline. Quality remains strong at 87, supported by the margin expansion. Sentiment at 50 is neutral, which may leave room for upside if next quarter's tirzepatide sales beat consensus. Watch for the next FDA decision on the oral GLP-1 candidate, expected in the second half of the year.

Shares in Eli Lilly edged higher after the FDA named the drugmaker to a pilot program that could shave up to 14 months off the factory inspection process. Seven companies were selected; Lilly and Regeneron were the only ones disclosed. The program targets pre-approval reviews, a step that can delay new drug launches. For Lilly, with its obesity and Alzheimer's pipelines pushing toward regulatory decisions, the timeline compression matters. The stock trades near the upper half of its 52-week range, with an Alpha Score of 74.1 driven by a momentum score of 95.9. Earnings growth hit 128.8% year over year, and net margins sit at 35%. Value scores lag at 54.4, reflecting the premium multiple. The next watch is an FDA decision on the company's next-generation obesity candidate, expected later this quarter.

Medicare's new obesity drug coverage begins Wednesday, but 82% of seniors are unaware of the benefit, according to a recent survey. That slow awareness ramp could delay the revenue impact for Eli Lilly and Novo Nordisk. LLY trades at a P/E of 53, supported by 47% revenue growth and 129% EPS growth last year. Net margins hit 35%. The stock sits near the top of its 52-week range, with Alpha Score momentum at 91 and quality at 87. Value and sentiment scores are middling. The next catalyst is the pace of Medicare enrollment and any update on Zepbound's formulary access. Watch for weekly prescription data and insurer coverage announcements through July.